WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
WASHINGTON (AP) — The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
The FINANCIAL — GlaxoSmithKline plc and Theravance, Inc. on April 30 announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilantero for the ...
Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...
With a handy lead in COPD, GlaxoSmithKline's Trelegy Ellipta has been positioned well as the leading triple-drug inhaler on the market. But with a major competitor gaining speed, GSK is looking to pad ...
Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results